Table II.
Tumor characteristics and patient’ follow-up in the interferon treatment/control groups.
| Author (year) | Median age (years) | Median size (cm) | Multiple (%) | Vessel invasion (%) | Cirrhosis (%) | Median follow-up (months) | 1-year rec. (n) | 2-year rec. (n) | >2-year rec. (n) | No. of deaths | Mortality rate (%) | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ikeda et al (2000) | 60/64.5 | 2.2/2 | 10/10 | 0/0 | 80/90 | 25/25 | 0/5 | 0/7 | 1/0 | 0/0 | 0.0/0.0 | (27) |
| Kubo et al (2002) | 61.9/60 | 2.5/2.6 | 0/0 | NA | 47/53 | 36/30 | 1/3 | 5/6 | 0/6 | 8/10 | 53.3/66.7 | (22) |
| Suou et al (2001) | 61/62 | 2/2.1 | 0/0 | NA | NA | NA | 1/3 | 2/7 | 2/8 | 0/6 | 0.0/27.3 | (37) |
| Miyaguchi et al (2002) | 66.2/65 | 2.8/2.4 | 27.2/33 | NA | 100/100 | NA | 3/10 | 3/14 | 1/0 | NA | NA | (38) |
| Shiratori et al (2003) | 61/63 | 2.2/2.3 | 34.7/36 | NA | 100/100 | 85/85 | 12/6 | 25/17 | 15/6 | 19/13 | 38.8/52.0 | (39) |
| Lin et al (2007) | 61.3/59 | 2/2.5 | 15/20 | NA | 90/100 | 27/27 | 56/4 | 5/6 | 3/3 | 4/5 | 20.0/50.0 | (14) |
| Chen et al (2012) | 50/49 | 3.5/3 | 21.5/14.8 | 30.8/24.4 | 53.8/55.2 | 63.8/63.8 | 37/35 | 51/55 | 27/21 | 43/41 | 32.3/30.4 | (19) |
| Mazzaferro et al (2006) | 65/67 | 3.4/3.2 | 22.4/25.7 | 19.7/23.0 | 94/88 | 45/45 | 25/24 | 40/39 | 4/8 | 17/23 | 22.4/31.1 | (4) |
| Sun et al (2006) | 52.2/50.4 | 4.3/4.9 | 13.6/12.7 | 76.2/75.4 | 83/88.1 | 36.5/36.5 | 32/49 | 52/62 | 15/9 | 38/60 | 32.2/50.8 | (18) |
| Lo et al (2007) | 52/51 | 5.5/5.7 | 17/27 | 48/35 | 48/83 | >36/>36 | 2/6 | 17/20 | 4/2 | 8/13 | 20.0/32.5 | (13) |
| Jeong et al (2007a) | 62/63 | 2/1.5 | 28.6/14.3 | NA | 70.2/75.8 | 37/37 | 0/2 | 9/13 | 11/17 | 2/12 | 4.8/28.6 | (19) |
| Jeong et al (2007b) | 68.5/67.5 | 1.5/1.8 | 43.8/37.5 | NA | 100/100 | 32/31 | 2/1 | 7/11 | 1/2 | 1/6 | 6.3/37.5 | (40) |
| Kudo et al (2007) | 65/66 | 1.8/1.5 | 19/23 | NA | 70.2/75.8 | NA | 2/6 | 12/13 | 12/17 | 6/37 | 14.0/44.0 | (21) |
| Hagihara et al (2011) | 63/67 | 1.8/2 | 28/28 | NA | NA | 44/44 | 5/33 | 17/76 | 1/25 | 2/49 | 5.4/33.8 | (41) |
NA, not available; rec., recurrence.